For people living with serious lung disease, such as autoimmune pulmonary alveolar proteinosis (aPAP), treatment is often not a one-time solution. Managing these conditions may require long-term monitoring, repeated procedures or ongoing therapies to help control symptoms and slow disease progression. Over time, standard or approved treatment options may become less effective, or may no longer be tolerated or appropriate due to other health conditions.
When standard treatment options are limited, you may want to explore additional care pathways with your healthcare team. Expanded access programs open a potential path to investigational treatments that can help manage your disease and support quality of life.
One Patient’s Road to Expanded Access
Niki’s path to investigational treatment options was not straight forward. As a young, active adult, she began having persistent irritation in the back of her throat and a lingering cough that did not improve. She consulted her primary care provider who suggested numerous treatments that proved unsuccessful, suggesting her diagnosis was incorrect. After many months of unanswered questions, Niki finally received a diagnosis of pulmonary alveolar proteinosis (PAP) at age 27 via an invasive open lung biopsy. This would later be identified as aPAP. "I started doing research to learn what I could about it because even the doctors didn’t know much about this disease,” Niki explained. At the time, little was known about autoimmune pulmonary alveolar proteinosis, and so there were very few treatment options.
Over the years, managing her symptoms has become more complicated. Niki experienced several lung infections and eventually developed lung fibrosis. As her disease progressed, she ultimately required a lung transplant after years of navigating a long and complex journey with her rare lung disease.
Understanding Expanded Access Programs and Why They Matter
Expanded access programs (EAPs), also known as compassionate use, may allow people living with serious or life-threatening diseases access to investigational treatments outside of a clinical trial. An investigational treatment is not approved by a regulatory agency—in this case the Food and Drug Administration—so it is still being tested to prove its effectiveness before being approved for widespread use.
These programs are typically considered when no approved treatment options are available, or when options have been exhausted. They are also considered when participation in a clinical trial is not possible. While clinical trials are often recommended, barriers such as strict eligibility requirements, location of the clinical trial, or other factors can make clinical trials inaccessible.
Expanded access programs do not replace clinical trials and are not guaranteed to be available. Individuals interested in participating in an expanded access program have to meet certain eligibility criteria in order to request access to the investigational treatment. Decisions about expanded access are made in close partnership with your healthcare provider, who can help determine whether this option may be appropriate for you.
When Standard Treatments Are No Longer Enough
Decades after her initial diagnosis, Niki found that the lack of treatment options available to her meant she could not adequately manage her symptoms. “There are limited treatment options for me, and the treatments that are available are no longer managing my disease,” she said. For Niki, this meant looking elsewhere. “I am very involved in the rare disease community and had researched and heard about investigational treatment for my disease.”
Unfortunately, Niki learned that she did not qualify for the clinical trial that was underway for her specific disease.
What Happens When Clinical Trials Aren’t an Option?
When a clinical trial is not an option, the path forward can feel uncertain. This is when having a conversation about expanded access begins. Niki worked closely with her specialist to see if an expanded access program was available as not all investigational treatments offer this option. When it became a possibility, her care team helped navigate the process to see if she could receive approval.
Reflecting on that moment, Niki shared, “It was a very emotional time for me, because my treatment options were running out. When my specialist called to tell me the investigational treatment would be available through the EAP, I was all in to try it!”
Advocating for Care and Exploring Treatment Options
From diagnosis to gaining access to an investigational treatment, Niki’s journey highlights the importance of staying informed and working closely with your healthcare team. Living with a chronic or rare lung disease often means navigating complex decisions over time. Talking openly with your healthcare provider about disease management, treatment options and whether expanded access programs may be right for you can help ensure your care continues to meet your needs. For Niki, finding a new treatment option through EAPs has meant hope, “This medication gives me hope that there may be a treatment to better manage my disease so I can continue doing the things I enjoy and living my life.”
Learn more about expanded access programs.
Educational content developed with support from Savara, Inc.
Blog last updated: June 23, 2026
